Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules
Neonatal immunization with hepatitis B (HB) vaccine induces protective levels of antibody (anti-HBs ≥10 IU/L) in a majority of vaccines. However, the duration of protection after HB vaccination in infants is unknown. A smaller proportion of children vaccinated beginning at birth with three doses of HB vaccine were found to have protective titers 5–10 years after initial vaccination. Long-term efficacy of HB vaccine depends mainly on peak antibody levels after vaccination, and subjects were observed to have lower levels of antibodies if they received the first dose of vaccine immediately after birth. The aim of our study was to compare the immunogenicity of two different HB vaccine schedules in infants born to HB surface antigen-negative mothers.
Anti-HBs titers in infants vaccinated with two different schedules were compared. Infants were vaccinated at 0, 2, and 9 months (group 1) or at 2, 4, and 9 months (group 2). In total, 267 blood samples were analyzed at a mean of 14.20 ± 2.39 months after the third vaccine dose. Sera were tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) using commercial enzyme immunoassay kits.
The geometric mean titers for anti-HBs were 95.00 and 379.51 IU/L and the rates of anti-HBs more than ≥100 IU/L were 57.7 and 94.9% in group 1 and 2 infants, respectively.
Delaying the first dose of the HB vaccine until 2 months after birth produces a higher immune response and can provide longer term protection.
- Herck, K, Damme, P (2008) Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J 27: pp. 861-869 CrossRef
- Demirjian, A, Levy, O (2009) Safety and efficacy of neonatal vaccination. Eur J Immunol 39: pp. 36-46 CrossRef
- Lu, CY, Chiang, BL, Chi, WK, Chang, MH, Ni, YH, Hsu, HM, Twu, SJ, Su, IJ, Huang, LM, Lee, CY (2004) Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40: pp. 1415-1420 CrossRef
- Bialek, SR, Bower, WA, Novak, R, Helgenberger, L, Auerbach, SB, Williams, IT, Bell, BP (2008) Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 27: pp. 881-885 CrossRef
- Hammitt, LL, Hennessy, TW, Fiore, AE, Zanis, C, Hummel, KB, Dunaway, E, Bulkow, L, McMahon, BJ (2007) Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 25: pp. 6958-6964 CrossRef
- McMahon, BJ, Bruden, DL, Petersen, KM, Bulkow, LR, Parkinson, AJ, Nainan, O, Khristova, M, Zanis, C, Peters, H, Margolis, HS (2005) Antibody levels of protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142: pp. 333-341
- del Canho, R, Grosheide, PM, Voogd, M, Huisman, WM, Heijtink, RA, Schalm, SW (1993) Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol 41: pp. 30-34 CrossRef
- Bassily, S, Kotkat, A, Gray, G, Hyams, KC, Brown, FM, Imam, IZ, Arthur, R (1995) Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. Am J Trop Med Hyg 53: pp. 419-422
- Stevens, CE, Toy, PT, Taylor, PE, Lee, T, Yip, HY (1992) Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 90: pp. 170-173
- Turkish Ministry of Health. Circular about extended program of immunization no: 1998/6856. Ankara: Turkish Ministry of Health.
- Turkish Ministry of Health. Circular about extended program of immunization no: 2009/7941. Ankara: Turkish Ministry of Health.
- Szmuness, W, Stevens, CE, Zang, EA, Harley, EJ, Kellner, A (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1: pp. 377-385 CrossRef
- Hadler, SC, Monzon, MA, Lugo, DR, Perez, M (1989) Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 7: pp. 106-110 CrossRef
- Jilg, W, Schmidt, M, Deinhardt, F (1989) Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 160: pp. 766-769
- Scheiermann, N, Gesemann, M, Maurer, C, Just, M, Berger, R (1990) Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 8: pp. 44-46 CrossRef
- Das, RR, Mathew, JL, Ratho, RK, Dutta, S (2009) Randomized clinical trial comparing hepatitis B vaccine administered by 0, 6, and 14 week versus 6, 10, and 14 week schedule in healthy infants. J Trop Pediatr 55: pp. 328-331 CrossRef
- Schalm, SW, Mazel, JA, Gast, GC, Heijtink, RA, Botman, MJ, Bänffer, JR, Cerards, LJ, Zwijnenberg, J, Fetter, WP, Nuijten, SM, Wladimiroff, YW, Chritensens, CML (1989) Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics 83: pp. 1041-1048
- Weeratna, RD, Brazolot Millan, CL, McCluskie, MJ, Siegrist, CA, Davis, HL (2001) Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 30: pp. 241-247 CrossRef
- Hu, Y, Wu, Q, Xu, B, Zhou, Z, Wang, Z, Zhou, YH (2008) Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine 26: pp. 6064-6067 CrossRef
- Petersen, KM, Bulkow, LR, McMahon, BJ, Zanis, C, Getty, M, Peters, H, Parkinson, AJ (2004) Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 23: pp. 650-655 CrossRef
- Seto, D, West, DJ, Ioli, VA (2002) Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J 21: pp. 793-795 CrossRef
- West, DJ, Watson, B, Lichtman, J, Hesley, TM, Hedberg, K (1994) Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 13: pp. 745-747 CrossRef
- Girisha, KM, Kamat, JR, Nataraj, G (2006) Immunological response to two hepatitis B vaccines administered in two different schedules. Indian J Pediatr 73: pp. 489-491 CrossRef
- Mathew JL, El Dib R, Mathew PJ, Boxall EH, Brok J. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database Syst Rev. 2008;16:CD006481.
- Immunity are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355: pp. 561-565 CrossRef
- Mast, EE, Weinbaum, CM, Fiore, AE, Alter, MJ, Bell, BP, Finelli, L, Rodewald, LE, Douglas, JM, Janssen, RS, Ward, JW (2005) Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54: pp. 1-31
- EUROHEP.NET. Recommendations for hepatitis B prevention strategies. Available at: www.eurohep.net. Accessed 22 March 2010.
- Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 38, Issue 4 , pp 269-273
- Cover Date
- Print ISSN
- Online ISSN
- Urban and Vogel
- Additional Links
- Hepatitis B vaccine
- Immunity duration
- Industry Sectors